Recipharm: sale of solid-dose manufacturing site in France
Recipharm has announced the sale of its solid-dose manufacturing site at Fontaine-lès-Dijon, France, to Astrea Pharma. The site’s capabilities reportedly fit Astrea’s goals to grow various processing, filling, and packaging technologies, and to expand its geographical research. well as a wide geographical reach.
Marc Funk, CEO of Recipharm, said, “This divestment will help strengthen our financial position and we see it as a positive step in streamlining our operations and consolidating our position as a top five global CDMO. I am pleased that this business will get a committed owner with the capacity and capability to develop it to its full potential. We will continue to develop and invest in our highly successful contract manufacturing business.”